2026-04-28T21:35:04Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/93412024-11-28T14:46:56Zcom_20.500.12105_2173com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19597col_20.500.12105_16927

00925njm 22002777a 4500 dc Cattrini, Carlo author Castro, Elena author Lozano, Rebeca author Zanardi, Elisa author Rubagotti, Alessandra author Boccardo, Francesco author Olmos, David author 2019-09-12 The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that several high-quality, randomized, controlled phase 3 trials have been conducted in this setting, no direct comparison is currently available among the different strategies. Inadequate power, absence of preplanning and small sample size frequently affect the subgroup analyses according to disease volume or patient's risk. The choice between ADT alone and ADT combined with docetaxel, abiraterone acetate, enzalutamide, apalutamide or radiotherapy to the primary tumor remains challenging. Factors that are related to the tumor, patient or drug side effects, currently guide these clinical decisions. This comprehensive review aims to indirectly compare the phase 3 trials in the mHSPC setting, in order to extrapolate data useful for treatment selection, providing also perspectives on future biomarkers. Cancers (Basel). 2019 ;11(9). pii: E1355 2072-6694 http://hdl.handle.net/10668/14537 http://hdl.handle.net/20.500.12105/9341 31547436 10.3390/cancers11091355 Cancers abiraterone acetate apalutamide docetaxel enzalutamide hormone-naïve prostate cancer hormone-sensitive prostate cancer radiotherapy Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer